29 studies found for:    saracatinib
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: saracatinib;   Drug: Placebo
2 Recruiting The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Condition: Pulmonary Lymphangioleiomyomatosis
Intervention: Drug: Saracatinib
3 Completed
Has Results
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Conditions: Breast Cancer;   Prostate Cancer;   Bone Neoplasms
Interventions: Drug: AZD0530;   Drug: Zoledronic Acid
4 Completed
Has Results
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IV Melanoma
Intervention: Drug: saracatinib
5 Not yet recruiting A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: AZD0530 100mg daily;   Drug: AZD0530 125mg daily;   Drug: Placebo
6 Terminated Saracatinib in Treating Patients With Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: saracatinib;   Other: hydrocortisone/placebo
7 Recruiting SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain
Condition: Cancer
Interventions: Drug: Saracatinib;   Drug: Placebo
8 Completed
Has Results
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Gastric Cancer;   Stage III Esophageal Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Intervention: Drug: saracatinib
9 Completed AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
10 Completed
Has Results
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Lung Metastases;   Malignant Pleural Effusion;   Recurrent Small Cell Lung Cancer
Intervention: Drug: saracatinib
11 Terminated
Has Results
AZD0530 in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
12 Active, not recruiting A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Condition: Osteosarcoma
Interventions: Drug: Saracatinib;   Drug: Placebo
13 Completed
Has Results
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: saracatinib;   Other: pharmacogenomic studies;   Other: pharmacological study;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysis
14 Completed
Has Results
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
15 Active, not recruiting Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Conditions: Invasive Thymoma and Thymic Carcinoma;   Recurrent Thymoma and Thymic Carcinoma;   Stage III Thymoma;   Stage IVA Thymoma;   Stage IVB Thymoma
Intervention: Drug: saracatinib
16 Completed
Has Results
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
17 Completed Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
Condition: Healthy
Intervention: Drug: AZD0530
18 Completed Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Paclitaxel;   Drug: Saracatinib;   Drug: Matched placebo
19 Completed Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Condition: Neoplasms
Interventions: Drug: AZD2171;   Drug: AZD0530
20 Completed AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Condition: Solid Tumor
Intervention: Drug: AZD0530

Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results
Indicates status has not been verified in more than two years